Factors associated with 12 week case-fatality in Staphylococcus aureus bacteraemia: a prospective cohort study.
Identifieur interne : 001006 ( PubMed/Corpus ); précédent : 001005; suivant : 001007Factors associated with 12 week case-fatality in Staphylococcus aureus bacteraemia: a prospective cohort study.
Auteurs : P. Braquet ; F. Alla ; C. Cornu ; F. Goehringer ; L. Piroth ; C. Chirouze ; M. Revest ; C. Lechiche ; X. Duval ; V. Le MoingSource :
- Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases [ 1469-0691 ] ; 2016.
English descriptors
- KwdEn :
- Aged, Bacteremia (drug therapy), Bacteremia (epidemiology), Bacteremia (mortality), Cross Infection (epidemiology), Cross Infection (mortality), Female, France (epidemiology), Humans, Male, Middle Aged, Penicillins (administration & dosage), Penicillins (therapeutic use), Prognosis, Prospective Studies, Staphylococcal Infections (drug therapy), Staphylococcal Infections (epidemiology), Staphylococcal Infections (mortality), Staphylococcus aureus, Survival Analysis, Tertiary Care Centers, Vancomycin (administration & dosage), Vancomycin (therapeutic use).
- MESH :
- chemical , administration & dosage : Penicillins, Vancomycin.
- drug therapy : Bacteremia, Staphylococcal Infections.
- epidemiology : Bacteremia, Cross Infection, France, Staphylococcal Infections.
- mortality : Bacteremia, Cross Infection, Staphylococcal Infections.
- chemical , therapeutic use : Penicillins, Vancomycin.
- Aged, Female, Humans, Male, Middle Aged, Prognosis, Prospective Studies, Staphylococcus aureus, Survival Analysis, Tertiary Care Centers.
Abstract
Staphylococcus aureus bacteraemia (SAB) is a frequent and deadly disease. Given the lack of a randomized trial, optimal first-line antibiotic treatment is still debated. Our aim was to identify prognostic factors in SAB patients and to analyse the impact of first-line antibiotics. The VIRSTA prospective cohort study was conducted in eight tertiary care centres in France. Consecutive incident adults in whom a blood culture drawn in participating centres grew S. aureus between April 2009 and October 2011 were prospectively followed for 12 weeks. Factors associated with 12-week case-fatality were identified by multivariate logistic regression. We enrolled 2091 patients and analysed survival in 1972 (median age 67.8 years, interquartile range 55.5-78.9; females 692/1972, 35.1%). SAB was nosocomial or healthcare-related in 1372/1972 (69.6%) of cases and the primary focus was unknown in 414/1972 (21.0%) of cases. Week 12 case-fatality rate was 671/1972 (34.0%). The main independent prognostic factors on multivariate analysis were age (adjusted OR by 10-year increment 1.56; 95% CI 1.44-1.69), septic shock (OR 5.11; 95% CI 3.84-6.80), metastatic cancer (OR 4.28; 95% CI 2.88-6.38), and unknown primary focus (OR 2.62; 95% CI 2.02-3.41). In the 1538 patients with methicillin-sensitive S. aureus (MSSA) bacteraemia, first-line empiric antistaphylococcal penicillins (OR 0.40; 95% CI 0.17-0.95) and vancomycin (OR 0.37; 95% CI 0.17-0.83), alone or combined with an aminoglycoside, were associated with better outcome compared with other antibiotics. There are few modifiable prognostic factors for SAB. Initiating empiric antibiotics with antistaphylococcal penicillins or vancomycin may be associated with better outcome in MSSA bacteraemia.
DOI: 10.1016/j.cmi.2016.07.034
PubMed: 27515395
Links to Exploration step
pubmed:27515395Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Factors associated with 12 week case-fatality in Staphylococcus aureus bacteraemia: a prospective cohort study.</title><author><name sortKey="Braquet, P" sort="Braquet, P" uniqKey="Braquet P" first="P" last="Braquet">P. Braquet</name><affiliation><nlm:affiliation>Department for Infectious Diseases and Tropical Medicine, Centre Hospitalier Universitaire de Montpellier, Montpellier, France; UMI 233 TransVIHMI, Université de Montpellier, Institut de Recherche sur le Développement, Montpellier, France. Electronic address: pit.braquet@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Alla, F" sort="Alla, F" uniqKey="Alla F" first="F" last="Alla">F. Alla</name><affiliation><nlm:affiliation>Université de Lorraine, Université Paris Descartes, Apemac, EA 4360, Nancy, France; INSERM, CIC-EC, CIE6, Nancy, France; CHU Nancy, Nancy, France.</nlm:affiliation></affiliation></author><author><name sortKey="Cornu, C" sort="Cornu, C" uniqKey="Cornu C" first="C" last="Cornu">C. Cornu</name><affiliation><nlm:affiliation>INSERM, CIC1407, Lyon, France; CHU Lyon, Service de Pharmacologie Clinique, Lyon, France; Université Lyon, UMR 5558, Lyon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Goehringer, F" sort="Goehringer, F" uniqKey="Goehringer F" first="F" last="Goehringer">F. Goehringer</name><affiliation><nlm:affiliation>Department of Infectious Diseases and Tropical Medicine, Centre Hospitalier Universitaire de Nancy, France.</nlm:affiliation></affiliation></author><author><name sortKey="Piroth, L" sort="Piroth, L" uniqKey="Piroth L" first="L" last="Piroth">L. Piroth</name><affiliation><nlm:affiliation>CHU de Dijon, UMR 1347-MERS, Université de Bourgogne, Dijon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Chirouze, C" sort="Chirouze, C" uniqKey="Chirouze C" first="C" last="Chirouze">C. Chirouze</name><affiliation><nlm:affiliation>UMR CNRS 6249 Chrono-environnement, Université de Bourgogne Franche-Comté, CHU de Besançon, Besançon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Revest, M" sort="Revest, M" uniqKey="Revest M" first="M" last="Revest">M. Revest</name><affiliation><nlm:affiliation>Infectious Diseases and Intensive Care Unit, Centre Hospitalier Universitaire de Rennes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Lechiche, C" sort="Lechiche, C" uniqKey="Lechiche C" first="C" last="Lechiche">C. Lechiche</name><affiliation><nlm:affiliation>Department for Infectious Diseases and Tropical Medicine, Centre Hospitalier Universitaire de Nîmes, Nîmes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Duval, X" sort="Duval, X" uniqKey="Duval X" first="X" last="Duval">X. Duval</name><affiliation><nlm:affiliation>Université Paris Diderot Sorbonne, Paris, France; IAME, INSERM, UMR 1137, CIC 1425, Paris, France; AP-HP, Hôpital Bichat Claude Bernard, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Le Moing, V" sort="Le Moing, V" uniqKey="Le Moing V" first="V" last="Le Moing">V. Le Moing</name><affiliation><nlm:affiliation>Department for Infectious Diseases and Tropical Medicine, Centre Hospitalier Universitaire de Montpellier, Montpellier, France; UMI 233 TransVIHMI, Université de Montpellier, Institut de Recherche sur le Développement, Montpellier, France. Electronic address: v-le_moing@chu-montpellier.fr.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27515395</idno><idno type="pmid">27515395</idno><idno type="doi">10.1016/j.cmi.2016.07.034</idno><idno type="wicri:Area/PubMed/Corpus">001006</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001006</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Factors associated with 12 week case-fatality in Staphylococcus aureus bacteraemia: a prospective cohort study.</title><author><name sortKey="Braquet, P" sort="Braquet, P" uniqKey="Braquet P" first="P" last="Braquet">P. Braquet</name><affiliation><nlm:affiliation>Department for Infectious Diseases and Tropical Medicine, Centre Hospitalier Universitaire de Montpellier, Montpellier, France; UMI 233 TransVIHMI, Université de Montpellier, Institut de Recherche sur le Développement, Montpellier, France. Electronic address: pit.braquet@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Alla, F" sort="Alla, F" uniqKey="Alla F" first="F" last="Alla">F. Alla</name><affiliation><nlm:affiliation>Université de Lorraine, Université Paris Descartes, Apemac, EA 4360, Nancy, France; INSERM, CIC-EC, CIE6, Nancy, France; CHU Nancy, Nancy, France.</nlm:affiliation></affiliation></author><author><name sortKey="Cornu, C" sort="Cornu, C" uniqKey="Cornu C" first="C" last="Cornu">C. Cornu</name><affiliation><nlm:affiliation>INSERM, CIC1407, Lyon, France; CHU Lyon, Service de Pharmacologie Clinique, Lyon, France; Université Lyon, UMR 5558, Lyon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Goehringer, F" sort="Goehringer, F" uniqKey="Goehringer F" first="F" last="Goehringer">F. Goehringer</name><affiliation><nlm:affiliation>Department of Infectious Diseases and Tropical Medicine, Centre Hospitalier Universitaire de Nancy, France.</nlm:affiliation></affiliation></author><author><name sortKey="Piroth, L" sort="Piroth, L" uniqKey="Piroth L" first="L" last="Piroth">L. Piroth</name><affiliation><nlm:affiliation>CHU de Dijon, UMR 1347-MERS, Université de Bourgogne, Dijon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Chirouze, C" sort="Chirouze, C" uniqKey="Chirouze C" first="C" last="Chirouze">C. Chirouze</name><affiliation><nlm:affiliation>UMR CNRS 6249 Chrono-environnement, Université de Bourgogne Franche-Comté, CHU de Besançon, Besançon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Revest, M" sort="Revest, M" uniqKey="Revest M" first="M" last="Revest">M. Revest</name><affiliation><nlm:affiliation>Infectious Diseases and Intensive Care Unit, Centre Hospitalier Universitaire de Rennes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Lechiche, C" sort="Lechiche, C" uniqKey="Lechiche C" first="C" last="Lechiche">C. Lechiche</name><affiliation><nlm:affiliation>Department for Infectious Diseases and Tropical Medicine, Centre Hospitalier Universitaire de Nîmes, Nîmes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Duval, X" sort="Duval, X" uniqKey="Duval X" first="X" last="Duval">X. Duval</name><affiliation><nlm:affiliation>Université Paris Diderot Sorbonne, Paris, France; IAME, INSERM, UMR 1137, CIC 1425, Paris, France; AP-HP, Hôpital Bichat Claude Bernard, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Le Moing, V" sort="Le Moing, V" uniqKey="Le Moing V" first="V" last="Le Moing">V. Le Moing</name><affiliation><nlm:affiliation>Department for Infectious Diseases and Tropical Medicine, Centre Hospitalier Universitaire de Montpellier, Montpellier, France; UMI 233 TransVIHMI, Université de Montpellier, Institut de Recherche sur le Développement, Montpellier, France. Electronic address: v-le_moing@chu-montpellier.fr.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</title><idno type="eISSN">1469-0691</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Bacteremia (drug therapy)</term><term>Bacteremia (epidemiology)</term><term>Bacteremia (mortality)</term><term>Cross Infection (epidemiology)</term><term>Cross Infection (mortality)</term><term>Female</term><term>France (epidemiology)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Penicillins (administration & dosage)</term><term>Penicillins (therapeutic use)</term><term>Prognosis</term><term>Prospective Studies</term><term>Staphylococcal Infections (drug therapy)</term><term>Staphylococcal Infections (epidemiology)</term><term>Staphylococcal Infections (mortality)</term><term>Staphylococcus aureus</term><term>Survival Analysis</term><term>Tertiary Care Centers</term><term>Vancomycin (administration & dosage)</term><term>Vancomycin (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Penicillins</term><term>Vancomycin</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Bacteremia</term><term>Staphylococcal Infections</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Bacteremia</term><term>Cross Infection</term><term>France</term><term>Staphylococcal Infections</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Bacteremia</term><term>Cross Infection</term><term>Staphylococcal Infections</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Penicillins</term><term>Vancomycin</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prognosis</term><term>Prospective Studies</term><term>Staphylococcus aureus</term><term>Survival Analysis</term><term>Tertiary Care Centers</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Staphylococcus aureus bacteraemia (SAB) is a frequent and deadly disease. Given the lack of a randomized trial, optimal first-line antibiotic treatment is still debated. Our aim was to identify prognostic factors in SAB patients and to analyse the impact of first-line antibiotics. The VIRSTA prospective cohort study was conducted in eight tertiary care centres in France. Consecutive incident adults in whom a blood culture drawn in participating centres grew S. aureus between April 2009 and October 2011 were prospectively followed for 12 weeks. Factors associated with 12-week case-fatality were identified by multivariate logistic regression. We enrolled 2091 patients and analysed survival in 1972 (median age 67.8 years, interquartile range 55.5-78.9; females 692/1972, 35.1%). SAB was nosocomial or healthcare-related in 1372/1972 (69.6%) of cases and the primary focus was unknown in 414/1972 (21.0%) of cases. Week 12 case-fatality rate was 671/1972 (34.0%). The main independent prognostic factors on multivariate analysis were age (adjusted OR by 10-year increment 1.56; 95% CI 1.44-1.69), septic shock (OR 5.11; 95% CI 3.84-6.80), metastatic cancer (OR 4.28; 95% CI 2.88-6.38), and unknown primary focus (OR 2.62; 95% CI 2.02-3.41). In the 1538 patients with methicillin-sensitive S. aureus (MSSA) bacteraemia, first-line empiric antistaphylococcal penicillins (OR 0.40; 95% CI 0.17-0.95) and vancomycin (OR 0.37; 95% CI 0.17-0.83), alone or combined with an aminoglycoside, were associated with better outcome compared with other antibiotics. There are few modifiable prognostic factors for SAB. Initiating empiric antibiotics with antistaphylococcal penicillins or vancomycin may be associated with better outcome in MSSA bacteraemia.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27515395</PMID><DateCompleted><Year>2017</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2017</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-0691</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>11</Issue><PubDate><Year>2016</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</Title><ISOAbbreviation>Clin. Microbiol. Infect.</ISOAbbreviation></Journal><ArticleTitle>Factors associated with 12 week case-fatality in Staphylococcus aureus bacteraemia: a prospective cohort study.</ArticleTitle><Pagination><MedlinePgn>948.e1-948.e7</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1198-743X(16)30291-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cmi.2016.07.034</ELocationID><Abstract><AbstractText>Staphylococcus aureus bacteraemia (SAB) is a frequent and deadly disease. Given the lack of a randomized trial, optimal first-line antibiotic treatment is still debated. Our aim was to identify prognostic factors in SAB patients and to analyse the impact of first-line antibiotics. The VIRSTA prospective cohort study was conducted in eight tertiary care centres in France. Consecutive incident adults in whom a blood culture drawn in participating centres grew S. aureus between April 2009 and October 2011 were prospectively followed for 12 weeks. Factors associated with 12-week case-fatality were identified by multivariate logistic regression. We enrolled 2091 patients and analysed survival in 1972 (median age 67.8 years, interquartile range 55.5-78.9; females 692/1972, 35.1%). SAB was nosocomial or healthcare-related in 1372/1972 (69.6%) of cases and the primary focus was unknown in 414/1972 (21.0%) of cases. Week 12 case-fatality rate was 671/1972 (34.0%). The main independent prognostic factors on multivariate analysis were age (adjusted OR by 10-year increment 1.56; 95% CI 1.44-1.69), septic shock (OR 5.11; 95% CI 3.84-6.80), metastatic cancer (OR 4.28; 95% CI 2.88-6.38), and unknown primary focus (OR 2.62; 95% CI 2.02-3.41). In the 1538 patients with methicillin-sensitive S. aureus (MSSA) bacteraemia, first-line empiric antistaphylococcal penicillins (OR 0.40; 95% CI 0.17-0.95) and vancomycin (OR 0.37; 95% CI 0.17-0.83), alone or combined with an aminoglycoside, were associated with better outcome compared with other antibiotics. There are few modifiable prognostic factors for SAB. Initiating empiric antibiotics with antistaphylococcal penicillins or vancomycin may be associated with better outcome in MSSA bacteraemia.</AbstractText><CopyrightInformation>Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Braquet</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department for Infectious Diseases and Tropical Medicine, Centre Hospitalier Universitaire de Montpellier, Montpellier, France; UMI 233 TransVIHMI, Université de Montpellier, Institut de Recherche sur le Développement, Montpellier, France. Electronic address: pit.braquet@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alla</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Université de Lorraine, Université Paris Descartes, Apemac, EA 4360, Nancy, France; INSERM, CIC-EC, CIE6, Nancy, France; CHU Nancy, Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cornu</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>INSERM, CIC1407, Lyon, France; CHU Lyon, Service de Pharmacologie Clinique, Lyon, France; Université Lyon, UMR 5558, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goehringer</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Tropical Medicine, Centre Hospitalier Universitaire de Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piroth</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>CHU de Dijon, UMR 1347-MERS, Université de Bourgogne, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chirouze</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>UMR CNRS 6249 Chrono-environnement, Université de Bourgogne Franche-Comté, CHU de Besançon, Besançon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Revest</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Diseases and Intensive Care Unit, Centre Hospitalier Universitaire de Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lechiche</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department for Infectious Diseases and Tropical Medicine, Centre Hospitalier Universitaire de Nîmes, Nîmes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duval</LastName><ForeName>X</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Université Paris Diderot Sorbonne, Paris, France; IAME, INSERM, UMR 1137, CIC 1425, Paris, France; AP-HP, Hôpital Bichat Claude Bernard, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Moing</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department for Infectious Diseases and Tropical Medicine, Centre Hospitalier Universitaire de Montpellier, Montpellier, France; UMI 233 TransVIHMI, Université de Montpellier, Institut de Recherche sur le Développement, Montpellier, France. Electronic address: v-le_moing@chu-montpellier.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>VIRSTA-AEPEI study group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Microbiol Infect</MedlineTA><NlmUniqueID>9516420</NlmUniqueID><ISSNLinking>1198-743X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010406">Penicillins</NameOfSubstance></Chemical><Chemical><RegistryNumber>6Q205EH1VU</RegistryNumber><NameOfSubstance UI="D014640">Vancomycin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016470" MajorTopicYN="N">Bacteremia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003428" MajorTopicYN="N">Cross Infection</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010406" MajorTopicYN="N">Penicillins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013203" MajorTopicYN="N">Staphylococcal Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013211" MajorTopicYN="N">Staphylococcus aureus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062606" MajorTopicYN="N">Tertiary Care Centers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014640" MajorTopicYN="N">Vancomycin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Antistaphylococcal penicillin</Keyword><Keyword MajorTopicYN="Y">Bacteraemia</Keyword><Keyword MajorTopicYN="Y">Prognostic factors</Keyword><Keyword MajorTopicYN="Y">Staphylococcus aureus</Keyword><Keyword MajorTopicYN="Y">Vancomycin</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Chirouze</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Curlier</LastName><ForeName>Elodie</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Descottes-Genon</LastName><ForeName>Cécile</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoen</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patry</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vettoretti</LastName><ForeName>Lucie</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chavanet</LastName><ForeName>Pascal</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eicher</LastName><ForeName>Jean-Christophe</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greusard</LastName><ForeName>Marie-Christine</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neuwirth</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Péchinot</LastName><ForeName>André</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piroth</LastName><ForeName>Lionel</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Célard</LastName><ForeName>Marie</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cornu</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delahaye</LastName><ForeName>François</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hadid</LastName><ForeName>Malika</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rausch</LastName><ForeName>Pascale</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coma</LastName><ForeName>Audrey</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galtier</LastName><ForeName>Florence</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Géraud</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jean-Pierre</LastName><ForeName>Hélène</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Le Moing</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sportouch</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reynes</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coma</LastName><ForeName>Audrey</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galtier</LastName><ForeName>Florence</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Géraud</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jean-Pierre</LastName><ForeName>Hélène</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Le Moing</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sportouch</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reynes</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coma</LastName><ForeName>Audrey</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galtier</LastName><ForeName>Florence</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Géraud</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jean-Pierre</LastName><ForeName>Hélène</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Le Moing</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sportouch</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reynes</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aissa</LastName><ForeName>Nejla</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doco-Lecompte</LastName><ForeName>Thanh</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goehringer</LastName><ForeName>François</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keil</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Letranchant</LastName><ForeName>Lorraine</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malela</LastName><ForeName>Hepher</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>May</LastName><ForeName>Thierry</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Selton-Suty</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bedos</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lavigne</LastName><ForeName>Jean-Philippe</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lechiche</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sotto</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duval</LastName><ForeName>Xavier</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Habensus</LastName><ForeName>Emila Ilic</ForeName><Initials>EI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iung</LastName><ForeName>Bernard</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leport</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Longuet</LastName><ForeName>Pascale</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruimy</LastName><ForeName>Raymond</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bellissant</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donnio</LastName><ForeName>Pierre-Yves</ForeName><Initials>PY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Le Gac</LastName><ForeName>Fabienne</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michelet</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Revest</LastName><ForeName>Matthieu</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tattevin</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thebault</LastName><ForeName>Elise</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alla</LastName><ForeName>François</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Braquet</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Erpelding</LastName><ForeName>Marie-Line</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Minary</LastName><ForeName>Laetitia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bès</LastName><ForeName>Michèle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Etienne</LastName><ForeName>Jérôme</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tristan</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandenesch</LastName><ForeName>François</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Belkum</LastName><ForeName>Alex</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanwamel</LastName><ForeName>Willem</ForeName><Initials>W</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>05</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>07</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>07</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27515395</ArticleId><ArticleId IdType="pii">S1198-743X(16)30291-9</ArticleId><ArticleId IdType="doi">10.1016/j.cmi.2016.07.034</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001006 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001006 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27515395
|texte= Factors associated with 12 week case-fatality in Staphylococcus aureus bacteraemia: a prospective cohort study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27515395" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |